【発明の名称】ムスカリン性レセプターアンタゴニスト

Title:

【発明の名称】ムスカリン性レセプターアンタゴニスト

Document Type and Number:

Japanese Patent JP2002517464

Kind Code:

A

Abstract:

Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modulator provided that at least one of said ligand is a muscarinic receptor antagonist. The multibinding compounds of this invention are useful in the treatment and prevention of diseases such as chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome, urinary incontinence, and the like.

More Like This:

JP2009508105	Fluorescent magnetic nanoparticles, their manufacturing methods and their uses
JP5172638	Method for evaluating lipid intramembrane orientation of membrane proteins
WO/2023/002943	BIOMARKER FOR PREDICTING PROGNOSIS OF CANCER PATIENT, METHOD FOR PREDICTING PROGNOSIS OF CANCER PATIENT, METHOD FOR PREDICTING EFFECT OF CANCER THERAPEUTIC DRUG ON CANCER PATIENT, AND KIT FOR PREDICTING PROGNOSIS OF CANCER PATIENT

Inventors:

Mom Men, Matthew
Ole, david
Griffin, John H.
Aggen, james

Application Number:

JP2000553111A

Publication Date:

June 18, 2002

Filing Date:

June 07, 1999

Export Citation:

Click for automatic bibliography generation Help

Assignee:

Advanced Medicine Incorporated

International Classes:

G01N33/53; A01N43/00; A01N55/02; A61K31/135; A61K31/33; A61K31/40; A61K31/404; A61K31/44; A61K31/4427; A61K31/4439; A61K31/445; A61K31/45; A61K31/4523; A61K31/454; A61K31/4545; A61K31/455; A61K31/498; A61K38/00; A61K38/16; A61K39/00; A61K39/395; A61K39/44; A61K51/00; A61P1/04; A61P1/06; A61P11/00; A61P11/06; A61P13/00; A61P43/00; C07B61/00; C07C217/10; C07D207/08; C07D209/00; C07D209/32; C07D209/48; C07D211/00; C07D211/44; C07D211/46; C07D221/24; C07D401/06; C07D401/12; C07D401/14; C07D403/06; C07D451/00; C07D451/06; C07D451/10; C07D487/18; C07K2/00; C07K4/00; C07K5/02; C40B20/00; C40B40/02; C40B40/04; C40B50/06; C40B60/10; G01N33/543; G01N33/566; (IPC1-7): C07C217/10; A61K31/4439; A61K31/445; A61K31/454; A61K31/4545; A61K31/498; A61P1/04; A61P1/06; A61P11/00; A61P11/06; A61P13/00; A61P43/00; C07B61/00; C07D207/08; C07D209/48; C07D211/46; C07D401/06; C07D401/12; C07D401/14; C07D403/06; C07D451/10; C07D487/18; C07K2/00; C07K4/00; G01N33/53; G01N33/543; G01N33/566

Attorney, Agent or Firm:

Shusaku Yamamoto

Previous Patent: α−１Ａアドレナリン作動性レセプターを調節する新規の治療剤

Next Patent: ＨＩＶ逆転写酵素のインヒビター